A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies.

Trial Profile

A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Alisertib (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Millennium; Takeda Oncology
  • Most Recent Events

    • 11 Sep 2017 Results (n=671) of population PK analysis using patient data from 6 Phase 1, 1 Phase 1/2 and 3 Phase 2 clinical trials published in the British Journal of Clinical Pharmacology
    • 10 Jun 2017 Biomarkers information updated
    • 14 Dec 2013 Phase II results for breast cancer patients presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top